Since the last newsletter update, the team at UroGPO has worked to improve member benefits by releasing additional contracts to drive value for our members, industry partners and valued customer accounts.

  • For the first quarter of 2016, Astellas Pharma has added a tiered rebate program to the discount already provided in the acquisition of Xtandi (enzalutamide). Now practices that purchase the drug through UroGPO can earn up to an additional 4 percent rebate, based on market share, in the drug basket.
  • New pharmaceutical offerings include Bayer’s Xofigo (Radium-223) and Ferring Pharmaceutical’s Firmagon (Degarelix). The Xofigo contract provides volume-based rebates to the practice, based on its quarterly utilization. The Firmagon contract is designed to allow members to earn more competitive pricing through monitoring and reporting on the utilization of Firmagon. Both contracts are in line with UroGPO’s desire to grow optimal industry partnerships, as well as utilization across key member groups.

Adding to the capital equipment offerings already available to members, UroGPO also announced a new partnership with BK Ultrasound. BK has done a great job in presenting pricing that is both competitive and creative. The contract offers ultrasound bundles for practices that need new machines, and there is discounted a-la-carte pricing available for practices that may need just a transducer or probe.The UroGPO team is committed to continuing to provide all the right contracts to support our members’ businesses. We are committed to keeping contracting competitive for the entire urology footprint and have additional offerings throughout 2016. As always, all contracts available to members are published and up to date in our member port, uTrack at Contracting and/or membership questions can be answered by e-mailing